These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 421235

  • 1. Enzymatic assay for the antitumor agent-N-(phosphonacetyl)-L-aspartic acid (PALA).
    Friedman J, Moore EC, Hall SW, Loo TL.
    Cancer Treat Rep; 1979 Jan; 63(1):85-8. PubMed ID: 421235
    [Abstract] [Full Text] [Related]

  • 2. An enzymatic technique for measuring N-phosphonacetyl-L-aspartic acid in tissues.
    Cooney DA, Karlowicz MG, Cubillan J, Roettger M, Jayaram HN.
    Cancer Treat Rep; 1978 Oct; 62(10):1503-7. PubMed ID: 361225
    [Abstract] [Full Text] [Related]

  • 3. Pharmacological disposition of N-(phosphonacetyl)-L-aspartate in humans.
    Loo TL, Friedman J, Moore EC, Valdivieso M, Marti JR, Stewart D.
    Cancer Res; 1980 Jan; 40(1):86-90. PubMed ID: 7349907
    [Abstract] [Full Text] [Related]

  • 4. N-(Phosphonacetyl)-L-aspartate inhibition of the enzyme complex of pyrimidine biosynthesis.
    Moore EC.
    Biochem Pharmacol; 1982 Oct 15; 31(20):3313-6. PubMed ID: 7150357
    [Abstract] [Full Text] [Related]

  • 5. Determination of N-(phosphonacetyl)-L-aspartic acid (PALA) in plasma and urine by high pressure liquid chromatography.
    Lankelma J, Penders PG, Leyva A, Pinedo HM.
    Eur J Cancer (1965); 1980 Nov 15; 16(11):1483-7. PubMed ID: 7227423
    [No Abstract] [Full Text] [Related]

  • 6. Determination of N-(Phosphonacetyl)-L-aspartic acid (PALA) in dog serum and urine by gas chromatography and selected lon monitoring.
    Strong JM, Kinney YE, Branfman AR, Cysyk RL.
    Cancer Treat Rep; 1979 May 15; 63(5):775-80. PubMed ID: 455314
    [Abstract] [Full Text] [Related]

  • 7. Kinetic parameters of aspartate transcarbamylase in human normal and tumoral cell lines.
    Baillon J, Guichard M, Malaise EP, Hervé G.
    Cancer Res; 1983 May 15; 43(5):2277-82. PubMed ID: 6831451
    [Abstract] [Full Text] [Related]

  • 8. Effect of N-(phosphonacetyl)-L-aspartate on 5-azacytidine metabolism in P388 and L1210 cells.
    Grant S, Rauscher F, Jakubowski A, Cadman E.
    Cancer Res; 1981 Feb 15; 41(2):410-8. PubMed ID: 6160908
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Gas chromatography and mass spectrometry of N-(phosphonacetyl)-L-aspartic acid.
    Branfman AR, Valia KH, Bruni RJ.
    J Chromatogr; 1978 Apr 01; 151(1):71-4. PubMed ID: 641126
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Mechanisms of sensitivity or resistance of murine tumors to N-(phosphonacetyl)-L-aspartate (PALA).
    Jayaram HN, Cooney DA, Vistica DT, Kariya S, Johnson RK.
    Cancer Treat Rep; 1979 Aug 01; 63(8):1291-302. PubMed ID: 476706
    [Abstract] [Full Text] [Related]

  • 16. Comparative physiological disposition of N-(phosphonacetyl)-L-aspartate in several animal species after intravenous and oral administration.
    Chadwick M, Silveira DM, MacGregor JA, Branfman AR, Liss RH, Yesair DW.
    Cancer Res; 1982 Feb 01; 42(2):627-32. PubMed ID: 7055806
    [Abstract] [Full Text] [Related]

  • 17. Effects of N-(phosphonacetyl)-L-aspartate on murine tumors and normal tissues in vivo and in vitro and the relationship of sensitivity to rate of proliferation and level of aspartate transcarbamylase.
    Johnson RK, Swyryd EA, Stark GR.
    Cancer Res; 1978 Feb 01; 38(2):371-8. PubMed ID: 620408
    [No Abstract] [Full Text] [Related]

  • 18. Application of a simple competitive protein-binding assay technique to the pharmacokinetics of N-(phosphonacetyl)-L-aspartate in humans.
    Erlichman C, Strong JM, Chabner BA.
    Cancer Res; 1980 Jun 01; 40(6):1902-6. PubMed ID: 7371023
    [Abstract] [Full Text] [Related]

  • 19. Analogs of L-aspartic acid in chemotherapy for cancer.
    Jayaram HN, Cooney DA.
    Cancer Treat Rep; 1979 Jun 01; 63(6):1095-108. PubMed ID: 38003
    [Abstract] [Full Text] [Related]

  • 20. Flux through the de novo pyrimidine pathway in vivo. Effect of N-phosphonacetyl-L-aspartate, a potent inhibitor of aspartate transcarbamylase.
    Monks A, Anderson LW, Strong J, Cysyk RL.
    J Biol Chem; 1983 Nov 25; 258(22):13564-9. PubMed ID: 6417130
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.